Drug intelligence / Profile preview

darunavir + ritonavir + emtricitabine + tenofovir disoproxil fumarate

Development stage
Unknown
Lead developer
Janssen Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

This drug is a fixed-dose combination antiretroviral regimen containing four active ingredients: darunavir, ritonavir, emtricitabine, and tenofovir disoproxil fumarate. It is used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Darunavir is an HIV-1 protease inhibitor that prevents viral replication by inhibiting the cleavage of viral polyproteins. Ritonavir acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A (CYP3A)-mediated metabolism, thereby increasing plasma concentrations of darunavir. Emtricitabine and tenofovir disoproxil fumarate are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase, blocking viral DNA synthesis and replication[4][6]. This combination provides a potent antiretroviral effect and is typically used as part of first-line therapy for HIV-1 infection.

Brand names
Truvada
Other names
TDF/FTC + DRV/r
02

Targets

Human immunodeficiency virus type 1 reverse transcriptaseCYP3A (CYP3A family)PR (Progesterone receptor)

Beyond the preview

Go deeper on darunavir + ritonavir + emtricitabine + tenofovir disoproxil fumarate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on darunavir + ritonavir + emtricitabine + tenofovir disoproxil fumarate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call